Industries > Pharma > Antiviral Drugs Treatment Market Report to 2031
Antiviral Drugs Treatment Market Report to 2031
By Application (HIV/AIDS, Influenza, Hepatitis, Herpes, Others), By Drug Class (DNA Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), By End user (Hospitals, Clinics, Other), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Global Antiviral Drugs Treatment Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Global Antiviral Drugs Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Antiviral Drugs Treatment report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antiviral Drugs Treatment Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Antiviral Drugs Treatment Market By Application
• HIV/AIDS
• Influenza
• Hepatitis
• Herpes
• Other
Antiviral Drugs Treatment Market by Drug Class
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Other
Antiviral Drugs Treatment Market by End User
• Hospitals
• Clinics
• Other
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antiviral Drugs Treatment Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antiviral Drugs Treatment Market with forecasts for By Application, By Drug Class, and by End user, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Antiviral Drugs Treatment Market report helps you
In summary, our 310+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Antiviral Drugs Treatment Market, with forecasts By Application, By Drug Class, and by End User each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antiviral Drugs Treatment market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Antiviral Drugs Treatment of the major companies involved in the Antiviral Drugs Treatment Market. Some of the company’s profiled in this report include
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc.
• Boehringer Ingelheim Corporation
• AstraZeneca AB,
• GlaxoSmithKline,
• Novartis AG
• Johnson & Johnson
• Merck & Co
• Bristol-Myers-Squibb,
• Abbott Laboratories
• Cipla Inc.
• Shionogi & Co., Ltd
• AbbVie
• Aurobindo Pharma
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
Our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Antiviral Drugs Treatment Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antiviral Drugs Treatment Market Report to 2031: By Application (HIV/AIDS, Influenza, Hepatitis, Herpes, Others), By Drug Class (DNA Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), By End user (Hospitals, Clinics, Other), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antiviral Drugs Treatment Market
2.1. Antiviral Drugs Treatment Market Definition
2.2. By Application Submarkets Definitions
2.3. By Drug Class Submarkets Definitions
2.4. By End user Submarkets Definitions
3. Antiviral Drugs Treatment Market Overview
3.1. Global Antiviral Drugs Treatment Market Size and Forecast by Region
3.2. Global Antiviral Drugs Treatment Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of viral infections.
3.3.1.2. Presence of pipeline products for HIV treatment
3.3.1.3. Surging geriatric population
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost associated in R&D
3.3.2.2. Rising prevalent resistance to neuraminidase inhibitors
3.3.2.3. Stringent government policies and rising preventive treatments and awareness.
3.3.3. Opportunities
3.3.3.1. Patent expiry of antiviral drugs boosts the market.
3.3.3.2. Increasing corona virus disease emerge need for antiviral drugs
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antiviral Drugs Treatment Market Analysis and Forecast 2021-2031, By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. HIV/AIDS
4.1.2. HIV needs protease to replicate, which includes atazanavir, darunavir, fosamprenavir, and lopinavir.
4.1.3. Influenza
4.1.4. . The neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir and peramivir) and M2 protein inhibitors are class of antiviral drugs to treat viral infection.
4.1.5. Hepatitis
4.1.6. Hepatitis C Virus (HCV) is transmitted through infective blood exposure, or by HCV contaminated blood and blood products.
4.1.7. Herpes
4.1.8. Herpes is caused by herpes simplex virus (HSV), which develops sores or blisters to form in or around the mouth or genitals.
4.1.9. Other (SARS-CoV-2 )
5. Global Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. DNA Polymerase Inhibitors
5.1.2. Inhibiting DNA synthesis is significant therapeutic strategy, widely used to treat the viral infections.
5.1.3. Reverse Transcriptase Inhibitors
5.1.4. The reverse-transcriptase inhibitors are class of antiretroviral drugs, majorly used to treat HIV infection and hepatitis B.
5.1.5. Protease Inhibitors
5.1.6. The antiretroviral protease inhibitors bind the catalytic site of the HIV protease.
5.1.7. Neuraminidase Inhibitors
5.1.8. Its blocks function of viral neuraminidases of the influenza virus and prevents replica by budding from the host cells.
5.1.9. Others
6. Global Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 End user (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.2. Pandemic emerge the demand for antiviral drugs.
6.1.3. Clinics
6.1.4. Increasing use of antiviral drugs for primary treatment include hepatitis B, herpes virus and influenza virus.
6.1.5. Other
7. North America Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antiviral Drugs Treatment Market Size and Forecast By Application
7.3. North America Antiviral Drugs Treatment Market Size and Forecast By Drug Class
7.4. North America Antiviral Drugs Treatment Market Size and Forecast By End User
7.5. U.S. Antiviral Drugs Treatment Market
7.5.1. Increasing approval of chronic hepatitis B infection in the region.
7.6. Canada Antiviral Drugs Treatment Market
7.6.1. Health Canada approved remdesivir antiviral drug in the region.
8. Europe Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antiviral Drugs Treatment Market Size and Forecast By Application
8.3. Europe Antiviral Drugs Treatment Market Size and Forecast By Drug Class
8.4. Europe Antiviral Drugs Treatment Market Size and Forecast By End User
8.5. UK Antiviral Drugs Treatment Market
8.5.1. Rising cases of herpes in the region, emerge the demand for antiviral drugs in the region.
8.6. Germany Antiviral Drugs Treatment Market
8.6.1. In Germany, the drugs available for influenza prophylaxis and therapy are amantadine and the neuraminidase inhibitors.
8.7. France Antiviral Drugs Treatment Market
8.8. Approval of amantadine neuraminidase inhibitors zanamivir and oseltamivir in the region to treat influenza.
8.9. Rest of Europe Antiviral Drugs Treatment Market
9. Asia Pacific Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antiviral Drugs Treatment Market Size and Forecast By Application
9.3. Asia Pacific Antiviral Drugs Treatment Market Size and Forecast By Drug Class
9.4. Asia Pacific Antiviral Drugs Treatment Market Size and Forecast By End User
9.5. China Antiviral Drugs Treatment Market
9.5.1. Development of various antiviral drugs in the region, Sinovac Biotech vaccine leads rapid immune response during trials of corona virus.
9.6. India Antiviral Drugs Treatment Market
9.7. Rising prevalence of hepatitis B in the region.
9.8. Japan Antiviral Drugs Treatment Market
9.8.1. Japanese government to increase stockpiles of Avigan, preparation for the outbreak of the novel influenza.
9.9. Rest of Asia Pacific Antiviral Drugs Treatment Market
10. Latin America Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antiviral Drugs Treatment Market Size and Forecast By Application
10.3. Latin America Antiviral Drugs Treatment Market Size and Forecast By Drug Class
10.4. Latin America Antiviral Drugs Treatment Market Size and Forecast By End User
10.4.1. Brazil Antiviral Drugs Treatment Market
10.4.1.1. The region has high number of people living with HIV, boost the demand for antiviral drug.
10.4.2. Mexico Antiviral Drugs Treatment Market
10.4.2.1. Influenza causes higher morbidity and mortality rates.
10.4.3. Rest of Latin America Antiviral Drugs Treatment Market
11. MEA Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antiviral Drugs Treatment Market Size and Forecast By Application
11.3. MEA Antiviral Drugs Treatment Market Size and Forecast By Drug Class
11.4. MEA Antiviral Drugs Treatment Market Size and Forecast By By End User
11.5. South Africa Antiviral Drugs Treatment Market
11.5.1.1. Increasing risk of developing HIV in the region need to prevent hospital acquired infections.
11.6. Rest of MEA Antiviral Drugs Treatment Market
12. Companies in the Antiviral Drugs Treatment Market
12.1. F. Hoffmann-La Roche Ltd
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Gilead Sciences Inc.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Boehringer Ingelheim Corporation
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. AstraZeneca AB
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. GlaxoSmithKline
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Novartis AG
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Johnson & Johnson
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Merck & Co
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Bristol-Myers-Squibb
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Abbott Laboratories
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antiviral Drugs Treatment Market Drivers & Restraints 2021
Table 7. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. HIV/AIDS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Influenza Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Influenza Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109 North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 121. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table125. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 155. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 156. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 161. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 177. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205 Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213 Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229 Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232 Leading 10 Antiviral Drugs Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 233. F. Hoffmann-La Roche Ltd Profile 2021 (CEO, HQ, Founded, Website)
Table 234. F. Hoffmann-La Roche Ltd Antiviral Drugs Treatment Selected Recent Contracts 2021 (Date, Programme Type, Details)
Table 235. F. Hoffmann-La Roche Ltd Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 236. Gilead Sciences Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 237. Gilead Sciences Inc Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 238. Boehringer Ingelheim Corporation Profile 2021 (CEO, HQ, Founded, Website)
Table 239. Boehringer Ingelheim Corporation Antiviral Drugs Treatment Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 240. Boehringer Ingelheim Corporation Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 241. AstraZeneca AB Profile 2021 (CEO, HQ, Founded, Website)
Table 242. AstraZeneca AB Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 243. AstraZeneca AB Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 244. GlaxoSmithKline Profile 2021 (CEO, HQ, Founded, Website)
Table 245 GlaxoSmithKline Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 246. Novartis AG Profile 2021 (CEO, HQ, Founded, Website)
Table 247. Novartis AG Antiviral Drugs Treatment Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 248 Novartis AG Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 249. Merck & Co Profile 2021 (CEO, HQ, Founded, Website)
Table 250. Merck & Co Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 251. Bristol-Myers-Squibb Profile 2021 (CEO, HQ, Founded, Website)
Table 252. Bristol-Myers-Squibb Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 253. Abbott Laboratories Profile 2021 (CEO, HQ, Founded, Website)
Table 254. Abbott Laboratories Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 255. Cipla Inc Profile 2021 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 256. Cipla Inc Total Company Sales 2015-2021 (US$m, AGR %)
Table 257. Cipla Inc Product Offering (Segment, Product Offerings)
Table 258. Other Companies Involved in the Antiviral Drugs Treatment Market (Company, Location)
LIST OF FIGURES
Figure 1. Antiviral Drugs Treatment Market Type Overview
Figure 2. Antiviral Drugs Treatment Market By Application Overview
Figure 3. Antiviral Drugs Treatment Market By Drug Class Overview
Figure 4. Antiviral Drugs Treatment Market End User Overview
Figure 5 Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M)
Figure 61. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 106. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 111. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M)
Figure 141. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 146. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M)
Figure 151. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antiviral Drugs Treatment Market Forecast End ser 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M)
Figure 161. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 166. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M)
Figure 171. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. F. Hoffmann-La Roche Ltd
2. Gilead Sciences Inc.
3. Boehringer Ingelheim Corporation
4. AstraZeneca AB,
5. GlaxoSmithKline,
6. Novartis AG
7. Johnson & Johnson
8. Merck & Co
9. Bristol-Myers-Squibb,
10. Abbott Laboratories
11. Cipla Inc.
12. Shionogi & Co., Ltd
13. AbbVie
14. Aurobindo Pharma
15. Dr Reddy's
16. FUJIFILM Toyama Chemical Co., Ltd.
17. Amgen Inc.
18. Alnylam Pharmaceuticals Inc
19. Vir Biotechnology Inc
20. Marinomed Biotech AG
21. Altimmune Inc.
22. BioNTech
23. Pfizer, Inc
24. CytoDyn Inc.
25. Heat Biologics, Inc.
26. Shanghai Fosun Pharmaceutical Co., Ltd.
27. Inovio Pharmaceuticals
28. Novavax Inc
29. Sanofi
30. Takeda Pharmaceutical Co. Ltd.
31. Vaxart Inc.
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antiviral Drugs Treatment Market
2.1. Antiviral Drugs Treatment Market Definition
2.2. By Application Submarkets Definitions
2.3. By Drug Class Submarkets Definitions
2.4. By End user Submarkets Definitions
3. Antiviral Drugs Treatment Market Overview
3.1. Global Antiviral Drugs Treatment Market Size and Forecast by Region
3.2. Global Antiviral Drugs Treatment Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of viral infections.
3.3.1.2. Presence of pipeline products for HIV treatment
3.3.1.3. Surging geriatric population
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost associated in R&D
3.3.2.2. Rising prevalent resistance to neuraminidase inhibitors
3.3.2.3. Stringent government policies and rising preventive treatments and awareness.
3.3.3. Opportunities
3.3.3.1. Patent expiry of antiviral drugs boosts the market.
3.3.3.2. Increasing corona virus disease emerge need for antiviral drugs
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antiviral Drugs Treatment Market Analysis and Forecast 2021-2031, By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. HIV/AIDS
4.1.2. HIV needs protease to replicate, which includes atazanavir, darunavir, fosamprenavir, and lopinavir.
4.1.3. Influenza
4.1.4. . The neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir and peramivir) and M2 protein inhibitors are class of antiviral drugs to treat viral infection.
4.1.5. Hepatitis
4.1.6. Hepatitis C Virus (HCV) is transmitted through infective blood exposure, or by HCV contaminated blood and blood products.
4.1.7. Herpes
4.1.8. Herpes is caused by herpes simplex virus (HSV), which develops sores or blisters to form in or around the mouth or genitals.
4.1.9. Other (SARS-CoV-2 )
5. Global Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. DNA Polymerase Inhibitors
5.1.2. Inhibiting DNA synthesis is significant therapeutic strategy, widely used to treat the viral infections.
5.1.3. Reverse Transcriptase Inhibitors
5.1.4. The reverse-transcriptase inhibitors are class of antiretroviral drugs, majorly used to treat HIV infection and hepatitis B.
5.1.5. Protease Inhibitors
5.1.6. The antiretroviral protease inhibitors bind the catalytic site of the HIV protease.
5.1.7. Neuraminidase Inhibitors
5.1.8. Its blocks function of viral neuraminidases of the influenza virus and prevents replica by budding from the host cells.
5.1.9. Others
6. Global Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 End user (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.2. Pandemic emerge the demand for antiviral drugs.
6.1.3. Clinics
6.1.4. Increasing use of antiviral drugs for primary treatment include hepatitis B, herpes virus and influenza virus.
6.1.5. Other
7. North America Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antiviral Drugs Treatment Market Size and Forecast By Application
7.3. North America Antiviral Drugs Treatment Market Size and Forecast By Drug Class
7.4. North America Antiviral Drugs Treatment Market Size and Forecast By End User
7.5. U.S. Antiviral Drugs Treatment Market
7.5.1. Increasing approval of chronic hepatitis B infection in the region.
7.6. Canada Antiviral Drugs Treatment Market
7.6.1. Health Canada approved remdesivir antiviral drug in the region.
8. Europe Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antiviral Drugs Treatment Market Size and Forecast By Application
8.3. Europe Antiviral Drugs Treatment Market Size and Forecast By Drug Class
8.4. Europe Antiviral Drugs Treatment Market Size and Forecast By End User
8.5. UK Antiviral Drugs Treatment Market
8.5.1. Rising cases of herpes in the region, emerge the demand for antiviral drugs in the region.
8.6. Germany Antiviral Drugs Treatment Market
8.6.1. In Germany, the drugs available for influenza prophylaxis and therapy are amantadine and the neuraminidase inhibitors.
8.7. France Antiviral Drugs Treatment Market
8.8. Approval of amantadine neuraminidase inhibitors zanamivir and oseltamivir in the region to treat influenza.
8.9. Rest of Europe Antiviral Drugs Treatment Market
9. Asia Pacific Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antiviral Drugs Treatment Market Size and Forecast By Application
9.3. Asia Pacific Antiviral Drugs Treatment Market Size and Forecast By Drug Class
9.4. Asia Pacific Antiviral Drugs Treatment Market Size and Forecast By End User
9.5. China Antiviral Drugs Treatment Market
9.5.1. Development of various antiviral drugs in the region, Sinovac Biotech vaccine leads rapid immune response during trials of corona virus.
9.6. India Antiviral Drugs Treatment Market
9.7. Rising prevalence of hepatitis B in the region.
9.8. Japan Antiviral Drugs Treatment Market
9.8.1. Japanese government to increase stockpiles of Avigan, preparation for the outbreak of the novel influenza.
9.9. Rest of Asia Pacific Antiviral Drugs Treatment Market
10. Latin America Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antiviral Drugs Treatment Market Size and Forecast By Application
10.3. Latin America Antiviral Drugs Treatment Market Size and Forecast By Drug Class
10.4. Latin America Antiviral Drugs Treatment Market Size and Forecast By End User
10.4.1. Brazil Antiviral Drugs Treatment Market
10.4.1.1. The region has high number of people living with HIV, boost the demand for antiviral drug.
10.4.2. Mexico Antiviral Drugs Treatment Market
10.4.2.1. Influenza causes higher morbidity and mortality rates.
10.4.3. Rest of Latin America Antiviral Drugs Treatment Market
11. MEA Antiviral Drugs Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antiviral Drugs Treatment Market Size and Forecast By Application
11.3. MEA Antiviral Drugs Treatment Market Size and Forecast By Drug Class
11.4. MEA Antiviral Drugs Treatment Market Size and Forecast By By End User
11.5. South Africa Antiviral Drugs Treatment Market
11.5.1.1. Increasing risk of developing HIV in the region need to prevent hospital acquired infections.
11.6. Rest of MEA Antiviral Drugs Treatment Market
12. Companies in the Antiviral Drugs Treatment Market
12.1. F. Hoffmann-La Roche Ltd
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Gilead Sciences Inc.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Boehringer Ingelheim Corporation
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. AstraZeneca AB
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. GlaxoSmithKline
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Novartis AG
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Johnson & Johnson
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Merck & Co
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Bristol-Myers-Squibb
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Abbott Laboratories
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antiviral Drugs Treatment Market Drivers & Restraints 2021
Table 7. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. HIV/AIDS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. HIV/AIDS Antiviral Drugs Treatment Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Influenza Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Influenza Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Herpes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 38. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 42. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. DNA Polymerase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Reverse Transcriptase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Protease Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Neuraminidase Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109 North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 121. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table125. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Europe Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 155. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 156. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 161. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Asia Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Asia Pacific Antiviral Drugs Treatment Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 177. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Asia Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. RoAPAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205 Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213 Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229 Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232 Leading 10 Antiviral Drugs Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 233. F. Hoffmann-La Roche Ltd Profile 2021 (CEO, HQ, Founded, Website)
Table 234. F. Hoffmann-La Roche Ltd Antiviral Drugs Treatment Selected Recent Contracts 2021 (Date, Programme Type, Details)
Table 235. F. Hoffmann-La Roche Ltd Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 236. Gilead Sciences Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 237. Gilead Sciences Inc Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 238. Boehringer Ingelheim Corporation Profile 2021 (CEO, HQ, Founded, Website)
Table 239. Boehringer Ingelheim Corporation Antiviral Drugs Treatment Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 240. Boehringer Ingelheim Corporation Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 241. AstraZeneca AB Profile 2021 (CEO, HQ, Founded, Website)
Table 242. AstraZeneca AB Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 243. AstraZeneca AB Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 244. GlaxoSmithKline Profile 2021 (CEO, HQ, Founded, Website)
Table 245 GlaxoSmithKline Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 246. Novartis AG Profile 2021 (CEO, HQ, Founded, Website)
Table 247. Novartis AG Antiviral Drugs Treatment Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 248 Novartis AG Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 249. Merck & Co Profile 2021 (CEO, HQ, Founded, Website)
Table 250. Merck & Co Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 251. Bristol-Myers-Squibb Profile 2021 (CEO, HQ, Founded, Website)
Table 252. Bristol-Myers-Squibb Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 253. Abbott Laboratories Profile 2021 (CEO, HQ, Founded, Website)
Table 254. Abbott Laboratories Antiviral Drugs Treatment Product Offering (Segment, Product Offerings)
Table 255. Cipla Inc Profile 2021 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 256. Cipla Inc Total Company Sales 2015-2021 (US$m, AGR %)
Table 257. Cipla Inc Product Offering (Segment, Product Offerings)
Table 258. Other Companies Involved in the Antiviral Drugs Treatment Market (Company, Location)
LIST OF FIGURES
Figure 1. Antiviral Drugs Treatment Market Type Overview
Figure 2. Antiviral Drugs Treatment Market By Application Overview
Figure 3. Antiviral Drugs Treatment Market By Drug Class Overview
Figure 4. Antiviral Drugs Treatment Market End User Overview
Figure 5 Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antiviral Drugs Treatment Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antiviral Drugs Treatment Submarket Forecast By Drug Class 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antiviral Drugs Treatment Submarket Forecast End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antiviral Drugs Treatment Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M)
Figure 61. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antiviral Drugs Treatment Market Forecast End user 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 106. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 111. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antiviral Drugs Treatment Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M)
Figure 141. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 146. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M)
Figure 151. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antiviral Drugs Treatment Market Forecast End ser 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M)
Figure 161. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antiviral Drugs Treatment Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M)
Figure 166. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antiviral Drugs Treatment Market Forecast By Drug Class 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M)
Figure 171. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antiviral Drugs Treatment Market Forecast End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antiviral Drugs Treatment Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. F. Hoffmann-La Roche Ltd
2. Gilead Sciences Inc.
3. Boehringer Ingelheim Corporation
4. AstraZeneca AB,
5. GlaxoSmithKline,
6. Novartis AG
7. Johnson & Johnson
8. Merck & Co
9. Bristol-Myers-Squibb,
10. Abbott Laboratories
11. Cipla Inc.
12. Shionogi & Co., Ltd
13. AbbVie
14. Aurobindo Pharma
15. Dr Reddy's
16. FUJIFILM Toyama Chemical Co., Ltd.
17. Amgen Inc.
18. Alnylam Pharmaceuticals Inc
19. Vir Biotechnology Inc
20. Marinomed Biotech AG
21. Altimmune Inc.
22. BioNTech
23. Pfizer, Inc
24. CytoDyn Inc.
25. Heat Biologics, Inc.
26. Shanghai Fosun Pharmaceutical Co., Ltd.
27. Inovio Pharmaceuticals
28. Novavax Inc
29. Sanofi
30. Takeda Pharmaceutical Co. Ltd.
31. Vaxart Inc.
Companies Profiled in the Report
1. F. Hoffmann-La Roche Ltd
2. Gilead Sciences Inc.
3. Boehringer Ingelheim Corporation
4. AstraZeneca AB,
5. GlaxoSmithKline,
6. Novartis AG
7. Johnson & Johnson
8. Merck & Co
9. Bristol-Myers-Squibb,
10. Abbott Laboratories
11. Cipla Inc.
12. Shionogi & Co., Ltd
13. AbbVie
14. Aurobindo Pharma
List of Companies Mentioned in the Report:
1. F. Hoffmann-La Roche Ltd
2. Gilead Sciences Inc.
3. Boehringer Ingelheim Corporation
4. AstraZeneca AB,
5. GlaxoSmithKline,
6. Novartis AG
7. Johnson & Johnson
8. Merck & Co
9. Bristol-Myers-Squibb,
10. Abbott Laboratories
11. Cipla Inc.
12. Shionogi & Co., Ltd
13. AbbVie
14. Aurobindo Pharma
15. Dr Reddy's
16. FUJIFILM Toyama Chemical Co., Ltd.
17. Amgen Inc.
18. Alnylam Pharmaceuticals Inc
19. Vir Biotechnology Inc
20. Marinomed Biotech AG
21. Altimmune Inc.
22. BioNTech
23. Pfizer Inc
24. CytoDyn Inc.
25. Heat Biologics, Inc.
26. Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
27. Inovio Pharmaceuticals
28. Novavax Inc
29. Sanofi
30. Takeda Pharmaceutical Co. Ltd.
31. Vaxart Inc.
List of Organizations Mentioned in the Report
1. World Health Organization
2. Hepatitis B Foundation
3. America HIV Epidemic Analysis Dashboard
4. American University Radio
5. Massachusetts Medical Society.
6. The European Medicines Agency (EMA)
7. US Food & Drug Administration
8. US National Library of Medicine
9. National Institutes of Health
10. the Biomedical Advanced Research and Development Authority (BARDA)
11. National Organisation for Rare Diseases
12. National Association for Biomedical Research
13. Center for Disease Control and Prevention CDC
14. Journal of the American college of Cardiology
15. National Foundation for Infectious Diseases.
16. Clinical Infectious Diseases
17. Center for Diseases Dynamics, Economics & Policy (CDDEP)
18. The Global Health Security Agenda (GHSA)
19. American Society of Microbiology
20. National Institute on Drug Abuse
21. The German Association for the Control of Virus Diseases,
22. The United Nations Office on Drugs and Crime (UNODC)
1. F. Hoffmann-La Roche Ltd
2. Gilead Sciences Inc.
3. Boehringer Ingelheim Corporation
4. AstraZeneca AB,
5. GlaxoSmithKline,
6. Novartis AG
7. Johnson & Johnson
8. Merck & Co
9. Bristol-Myers-Squibb,
10. Abbott Laboratories
11. Cipla Inc.
12. Shionogi & Co., Ltd
13. AbbVie
14. Aurobindo Pharma
List of Companies Mentioned in the Report:
1. F. Hoffmann-La Roche Ltd
2. Gilead Sciences Inc.
3. Boehringer Ingelheim Corporation
4. AstraZeneca AB,
5. GlaxoSmithKline,
6. Novartis AG
7. Johnson & Johnson
8. Merck & Co
9. Bristol-Myers-Squibb,
10. Abbott Laboratories
11. Cipla Inc.
12. Shionogi & Co., Ltd
13. AbbVie
14. Aurobindo Pharma
15. Dr Reddy's
16. FUJIFILM Toyama Chemical Co., Ltd.
17. Amgen Inc.
18. Alnylam Pharmaceuticals Inc
19. Vir Biotechnology Inc
20. Marinomed Biotech AG
21. Altimmune Inc.
22. BioNTech
23. Pfizer Inc
24. CytoDyn Inc.
25. Heat Biologics, Inc.
26. Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
27. Inovio Pharmaceuticals
28. Novavax Inc
29. Sanofi
30. Takeda Pharmaceutical Co. Ltd.
31. Vaxart Inc.
List of Organizations Mentioned in the Report
1. World Health Organization
2. Hepatitis B Foundation
3. America HIV Epidemic Analysis Dashboard
4. American University Radio
5. Massachusetts Medical Society.
6. The European Medicines Agency (EMA)
7. US Food & Drug Administration
8. US National Library of Medicine
9. National Institutes of Health
10. the Biomedical Advanced Research and Development Authority (BARDA)
11. National Organisation for Rare Diseases
12. National Association for Biomedical Research
13. Center for Disease Control and Prevention CDC
14. Journal of the American college of Cardiology
15. National Foundation for Infectious Diseases.
16. Clinical Infectious Diseases
17. Center for Diseases Dynamics, Economics & Policy (CDDEP)
18. The Global Health Security Agenda (GHSA)
19. American Society of Microbiology
20. National Institute on Drug Abuse
21. The German Association for the Control of Virus Diseases,
22. The United Nations Office on Drugs and Crime (UNODC)
Download sample pages
Complete the form below to download your free sample pages for Antiviral Drugs Treatment Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Antiviral Drugs Treatment Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?
What are the dynamic growth sectors? where are the regional business opportunities?
Which technologies will prevail and who are the leading companies succeeding in these sectors and why?
If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.
If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Rare Diseases Market Report 2021-2031
As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.
02 March 2021
Visiongain Publishes Respiratory Inhalers Market Report 2021-2031
Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.
26 February 2021
Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031
The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.
22 February 2021
Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031
The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.
22 February 2021
